|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||81.70 - 83.30|
|52 Week Range||73.80 - 126.85|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||16.72|
|Earnings Date||Feb 13, 2020|
|Forward Dividend & Yield||1.00 (1.22%)|
|Ex-Dividend Date||May 31, 2019|
|1y Target Est||144.23|
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Dr. Howard Mayer as Executive Vice President and Head of Research and Development, effective December 1st, 2019. Based in Cambridge, Mass, U.S., Dr. Mayer will report directly to David Meek, CEO, Ipsen and serve on the Executive Leadership Team. David Meek, CEO, Ipsen, commented, “As Ipsen enters its next phase of growth, it is my great pleasure to appoint Dr. Mayer to lead Ipsen’s R&D organization.
The Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY) takes note of the proposed demerger of Mayroy and the internal reclassification of its Ipsen shares, resulting in a request for a waiver to the obligation to file a public offer. This project was announced today by Mayroy, controlling shareholder of Ipsen, holding 56.40%1 of the share capital and 72.08%1 of the company's voting rights. According to Mayroy’s press release, the family shareholdings controlling Ipsen will remain unchanged following these operations, with the ongoing pre-eminence of the concert formed by Anne and Henri Beaufour.
ADR: IPSEY) and Blueprint Medicines Corporation (BPMC) today announced Ipsen, through its subsidiary Clementia Pharmaceuticals, and Blueprint Medicines have entered into an exclusive, worldwide license agreement for the development and commercialization of BLU-782, an oral, highly selective investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
The results, which included preliminary safety and efficacy data, were presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona , 7-10 September 2019 .